anti-F7 antibody product blog
Tags: Antibody; Polyclonal Antibody; anti-F7 antibody; FACTOR VII;
The F7 f7 (Catalog #MBS512050) is an Antibody produced from Sheep and is intended for research purposes only. The product is available for immediate purchase.Suitable as a source of biotinylated antibodies to Factor VII. Researchers should empirically determine the suitability of the F7 f7 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
The F7 f7 product has the following accession number(s) (GI #180334) (Uniprot Accession #P08709). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 ug/mL (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 gamma-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and an 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate FX and FIX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of FXa, and also by Antithrombin (ATIII) in the presence of heparin1-3.
Immunogen: Human FVII purified from plasma. Buffer: Phosphate-buffered saline containing 1 mg/mL bovine albumin and 0.1% sodium azide (w/v), pH 7.4. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing F7 are readily searchable from our website. Different antibodies against the same target such as F7 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.